---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-161593"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:45:48.296014+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Taysha grants performance-based options to CEO (666.5K), President (477.2K), CFO (268K)

## Summary
- CEO Sean Nolan receives 666,500 options; President Sukumar Nagendran 477,150; CFO Kamran Alam 267,975.
- Awards tied to clinical, regulatory, and corporate milestones by Dec 31, 2023; vest over 3 years.
- Board revised director compensation: initial equity grant set at 43,800 shares; annual at 36,200 shares.
- Options under 2020 Stock Incentive Plan; intended to strengthen pay-for-performance alignment.
- No departure reported; grants are one-time performance-based equity incentives.

## SEC filing metadata
- accession: 0001193125-23-161593
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523161593/0001193125-23-161593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523161593/d480804d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-161593
- JSON: https://secwatch.observer/filing/0001193125-23-161593.json
- Plain text: https://secwatch.observer/filing/0001193125-23-161593.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.